Hence, pharmacological means to increase α-MSH bioavailability, e.g. via inhibition of PRCP, could provide a therapeutic strategy to treat atherosclerotic cardiovascular disease, but future mechanistic experiments will be instrumental to clarify the role of PRCP in atherosclerosis. This evidence concerns the gene PRCP and atherosclerosis.